Skip to main content
. Author manuscript; available in PMC: 2010 Jul 23.
Published in final edited form as: Cell. 2009 Jul 23;138(2):271–285. doi: 10.1016/j.cell.2009.05.046

Figure 3. IAP+/- HSCs have a competitive disadvantage relative to wild-type HSCs due to macrophages.

Figure 3

(A) MFI of CD47 on IAP+/+, IAP+/-, and IAP-/- LT-HSC. (B) Donor chimerism analysis for transplants of IAP+/+, GFP+ or IAP+/-, GFP+ marrow cells. Loss of donor chimerism is shown using Kaplan-Meier curves. (C) Experimental design for assessing effect of CD47 heterozygosity during LPS challenge. (D) Change in percent chimerism of host KLS cells compared to expected chimerism based on peripheral blood granulocytes is shown. Error bars represent 1 SD and p-values were obtained by ANOVA statistics. n=5 for IAP+/+ with clodronate (CLOD), n= 7 for IAP+/+ with control (CTRL), n=4 for IAP+/- with clodronate, n=7 for IAP+/- with control. (E) Results of in vivo phagocytosis assay comparing IAP+/+ and IAP+/- c-Kit enriched cells. Percent recipient GFP+ F4/80 cells is shown (n= 3 for each group, error bars represent 1 SD).